1.5 CE Credit(s)
Expires: September 30, 2025
This activity is designed to meet the educational needs of clinicians involved in the diagnosis and management of patients with hereditary angioedema (HAE).
Upon completion of this activity, participants should be better able to:
Jointly provided by RMEI Medical Education, LLC and the US Hereditary Angioedema Association. Funding provided by the US Hereditary Angioedema Association. No commercial support is provided for this accredited continuing education activity.
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and the US Hereditary Angioedema Association. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
RMEI Medical Education, LLC designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-9999-23-015-H01-P)
Type of Activity: Knowledge
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hour(s).
To receive credit, participants must review the activity content and successfully complete the evaluation to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
Aleena Banerji, MD
Clinical Director, Allergy and Clinical Immunology
Director, Drug Allergy Program
Associate Professor, Medicine
Division of Rheumatology, Allergy and Immunology
Harvard Medical School
Boston, MA
Jonathan Bernstein, MD
Professor
Clinical Medicine
University of Cincinnati
College of Medicine
Cincinnati, OH
Paula Busse, MD
Professor
Associate Professor
Clinical Immunology
Mount Sinai Hospital
New York, NY
Sandra C. Christiansen, MD
Professor, Medicine
Department of Medicine
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA
Mark Davis-Lorton, MD
Director
Clinical Immunology
Winthrop-University Hospital
Mineola, NY
William R. Lumry, MD
Clinical Professor, Internal Medicine
University of Texas Southwestern Medical School
Dallas, TX
Huamin Henry Li, MD, PhD
President
Institute for Asthma and Allergy
Chevy Chase, MD
Michael Manning, MD
President
Allergy, Asthma and Immunology Associates, LTD
Scottsdale, AZ
Raffi Tachdjian, MD, MPH
Assistant Clinical Professor of Medicine and Pediatrics
Division of Allergy and Clinical Immunology, David Geffen School of Medicine at the University of California – Los Angeles (UCLA).
Los Angeles, CA
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Aleena Banerji, MD, has relevant financial relationships with BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., Pharvaris, Takeda (Consultant); Astria Therapeutics, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., KalVista Pharma, Takeda (Researcher).
Jonathan Bernstein, MD, has relevant financial relationships with BioCryst Pharmaceuticals, BioMarin Pharmaceutical Inc., CSL Behring, Cycle, Intellia Technologies Inc., Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharming Group N.V., Pharvaris, Shire/Takeda (Consultant); BioCryst Pharmaceuticals, BioMarin Pharmaceutical Inc., CSL Behring, Cycle, Intellia Technologies Inc., Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharming Group N.V., Pharvaris, Shire/Takeda (Researcher); BioCryst Pharmaceuticals, CSL Behring, Pharming Group N.V., Shire/Takeda (Speaker/ Speaker’s Bureau).
Paula Busse, MD, has relevant financial relationships with BioCryst Pharmaceuticals, BioMarin Pharmaceutical Inc., CSL Behring, CVS/Specialty, Ionis Pharmaceuticals, Inc., KalVista Pharma, Novartis, Pharvaris, Regeneron, Takeda (Consultant); CSL Behring, KalVista Pharma, Takeda (Grant/Research Support).
Sandra C. Christiansen, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
Mark Davis-Lorton, MD, has relevant financial relationships with BioCryst Pharmaceuticals, Pharming Group N.V., Pharvaris, Takeda (Advisor); BioCryst Pharmaceuticals, Pharming Group N.V., Takeda (Speaker/Speaker’s Bureau).
Huamin Henry Li, MD, PhD, has relevant financial relationships with Astria, BioCryst Pharmaceuticals, BioMarin Pharmaceutical Inc., CSL Behring, Intelia Technologies Inc., KalVista Pharma, Pharming Group N.V., Pharvaris, Takeda (Grant/Research Support); BioCryst Pharmaceuticals, CSL Behring, Pharming Group N.V., Takeda (Speaker/Speaker’s Bureau).
William Lumry, MD, has relevant financial relationships with Astria, BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia Therapeutics, Inc., KalVista Pharma, Magellan, Optum, Pharming Group N.V., Pharvaris, Shire, Takeda (Consultant); CSL Behring, Grifols S.A., Ionis Pharmaceuticals, Inc., KalVista Pharma, Shire/Takeda, Teva Pharmaceuticals USA (Grant/Research Support); AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, Grifols S.A., GSK, OptiNose, Inc, Pharming Group N.V., Shire/Takeda, Sanofi/ Regeneron (Speakers’ Bureau).
Michael Manning, MD, has relevant financial relationships with BioCryst Pharmaceuticals, CSL Behring, KalVista Pharma, Pharming Group N.V., Takeda (Consultant); BioCryst Pharmaceuticals, CSL Behring, KalVista Pharma, Pharming Group N.V., Takeda (Independent Contractor, including contracted research); BioCryst Pharmaceuticals, CSL Behring, Pharming Group N.V., Takeda (Speaker/Speaker’s Bureau).
Raffi Tachdjian, MD, MPH, has relevant financial relationships with BioCryst Pharmaceuticals, CSL Behring, KalVista Pharma, Pharming Group N.V., Takeda (Advisor); BioCryst Pharmaceuticals, CSL Behring, Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharming Group N.V., Pharvaris, Takeda (Independent Contractor); BioCryst Pharmaceuticals, CSL Behring, Pharming Group N.V., Takeda (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
